IBA Dosimetry and ScandiDos enters a partnership in USA and Canada to offer a complete range of solutions for Radiation Therapy plan verification
- IBA Dosimetry enters into non-exclusive distribution agreement for Scandidos’ Delta4®PT (Pre Treatment) for the US and Canada
- Partnership offers clinical users to select patient treatment validation solution that best suits needs to maximize efficiency and minimize errors in radiation therapy treatment
Schwarzenbruck-Germany/Uppsala-Sweden, 17 January, 2013 – IBA Dosimetry and ScandiDos, the two global innovation leaders in the field of dosimetry solutions and services for radiation therapy cancer treatment, jointly announce that the two companies have entered into a non-exclusive agreement in the USA and Canada for the distribution by IBA Dosimetry of the ScandiDos patient treatment validation system Delta4PT. The distribution agreement will allow radiation therapy clinics to select from the most complete range of high quality patient treatment validation solutions from a single source.
“Patient safety and customer efficiency is the driving motivation at IBA Dosimetry. With a growing demand for rotational plan verification in North America we are pleased to join forces with ScandiDos to provide our customer base the choice between a complete range of patient treatment validation solutions including MatriXX, Delta4PT and COMPASS,” says Rob Plompen, President of IBA Dosimetry.
“At ScandiDos we are very pleased to be able to provide our pre-treatment QA solutions to the extended network of IBA Dosimetry customers in the USA and Canada,” says Görgen Nilsson, CEO at ScandiDos. “With this agreement we trust that clinics can chose from the best QA solutions for their needs and implement new advanced treatment technologies faster in a safe way and thereby improve the survival and the quality of life for their patients.”
About IBA
IBA (Ion Beam Applications S.A.) is the global high-tech leader in next generation radiation therapy and diagnostics of cancer. The Company’s expertise lies in the development of next generation proton therapy technologies and radiopharmaceuticals that provide oncology care providers with premium quality services and equipment, including IBA’s leading fully integrated IntegraLab® radiopharmacy system, and Dosimetry advanced solutions for Quality Assurance of medical equipment and increased patient safety.
Headquartered in Belgium and employing more than 1,200 people worldwide, IBA currently has installed systems across Europe and the US and is expanding into emerging markets. The Company is focused on building sustainable global growth for investors by providing solutions in the fight against cancer.
IBA is listed on the pan-European stock exchange EURONEXT. Further information can be found at:
http://www.iba-worldwide.com
About ScandiDos:
ScandiDos is the innovative company that introduced the new QA standard in advanced radiotherapy by moving into the era of 3D and 4D volumetric dosimetry.
ScandiDos grew out of a recognized need for practical clinical solutions for new advanced radiation therapy technologies. ScandiDos mission is to improve the treatment of patients with cancer worldwide by reinforcing the confidence in radiotherapy clinics using innovative solutions that further individualize the radiation treatment, making the process safe and efficient.
ScandiDos, with offices in Uppsala, Sweden, Madison, WI, USA and Beijing, China, is a privately held company. For more information visit www.scandidos.com
For more information about this press release contact:
At IBA: Mike Meyers, President Americas IBA Dosimetry;
Mike.Meyer@iba-group.be
At Scandidos: Görgen Nilsson, CEO ScandiDos;
Gorgen.Nilsson@ScandiDos.com
MatriXX and COMPASS are trademarks of IBA
® Delta4 is a registered trademark of ScandiDos AB